Gelesis Holdings Company Description
Gelesis Holdings, Inc., a commercial stage biotherapeutics company, developing a biomimicry to treat the genesis of obesity and GI-related chronic diseases.
It also offers PLENITY, an orally administered, non-stimulant, and non-systemic aid for weight management.
In addition, the company develops GS200 for weight loss in prediabetes and type 2 diabetes; and GS500 for functional constipation.
Further, it develops pre-clinical product GS300 for non-alcoholic fatty liver disease/non-alcoholic steatohepatitis.
Gelesis Holdings, Inc. was incorporated in 2006 and is headquartered in Boston, Massachusetts. On October 30, 2023, Gelesis Holdings, Inc., along its affiliates, filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the District of Delaware.
| Country | United States |
| Founded | 2006 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 93 |
| CEO | Yishai Zohar |
Contact Details
Address: 501 Boylston Street Boston, Delaware 02116 United States | |
| Phone | 617 456 4718 |
| Website | gelesis.com |
Stock Details
| Ticker Symbol | GLSHQ |
| Exchange | OTCMKTS |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| ISIN Number | US36850R2040 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Alessandro Sannino Ph.D. | Co-Inventor and Lead Project Scientist |
| Joy Bauer M.S., RDN | Chief Nutrition Officer of Plenity |